Ligand Pharmaceuticals Incorporated (LGND)
NASDAQ: LGND · Real-Time Price · USD
232.34
+18.90 (8.85%)
At close: Apr 14, 2026, 4:00 PM EDT
231.39
-0.95 (-0.41%)
After-hours: Apr 14, 2026, 4:19 PM EDT
Ligand Pharmaceuticals Revenue
In the year 2025, Ligand Pharmaceuticals had annual revenue of $268.09M with 60.40% growth. Ligand Pharmaceuticals had revenue of $59.67M in the quarter ending December 31, 2025, with 39.37% growth.
Revenue (ttm)
$268.09M
Revenue Growth
+60.40%
P/S Ratio
17.41
Revenue / Employee
$5,703,979
Employees
47
Market Cap
4.63B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 268.09M | 100.95M | 60.40% |
| Dec 31, 2024 | 167.13M | 35.82M | 27.28% |
| Dec 31, 2023 | 131.31M | -64.93M | -33.09% |
| Dec 31, 2022 | 196.25M | -45.30M | -18.75% |
| Dec 31, 2021 | 241.54M | 77.98M | 47.68% |
| Dec 31, 2020 | 163.56M | 43.28M | 35.98% |
| Dec 31, 2019 | 120.28M | -131.17M | -52.17% |
| Dec 31, 2018 | 251.45M | 110.35M | 78.21% |
| Dec 31, 2017 | 141.10M | 32.13M | 29.48% |
| Dec 31, 2016 | 108.97M | 37.06M | 51.53% |
| Dec 31, 2015 | 71.91M | 7.38M | 11.43% |
| Dec 31, 2014 | 64.54M | 15.57M | 31.78% |
| Dec 31, 2013 | 48.97M | 17.59M | 56.02% |
| Dec 31, 2012 | 31.39M | 1.35M | 4.50% |
| Dec 31, 2011 | 30.04M | 6.50M | 27.61% |
| Dec 31, 2010 | 23.54M | -15.40M | -39.55% |
| Dec 31, 2009 | 38.94M | 11.63M | 42.56% |
| Dec 31, 2008 | 27.32M | 14.42M | 111.84% |
| Dec 31, 2007 | 12.89M | 8.92M | 224.21% |
| Dec 31, 2006 | 3.98M | -6.24M | -61.07% |
| Dec 31, 2005 | 10.22M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Apellis Pharmaceuticals | 1.00B |
| Corcept Therapeutics | 761.41M |
| Amicus Therapeutics | 634.21M |
| TG Therapeutics | 616.29M |
| NewAmsterdam Pharma Company | 22.50M |
| Crinetics Pharmaceuticals | 7.70M |
| CRISPR Therapeutics AG | 3.51M |
| Dianthus Therapeutics | 2.04M |
LGND News
- 13 hours ago - Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI® (sparsentan) in FSGS - GlobeNewsWire
- 19 days ago - Ligand Advances Strategic Growth with Expanded and Strengthened Business Development Team - GlobeNewsWire
- 4 weeks ago - Ligand Pharmaceuticals Is A Low-Risk Way To Bet On Biopharma Growth: Analyst - Benzinga
- 5 weeks ago - Ligand to Participate in March Investor Conferences - GlobeNewsWire
- 6 weeks ago - Ligand Reports Fourth Quarter and Full Year 2025 Financial Results - GlobeNewsWire
- 2 months ago - Ligand to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026 - GlobeNewsWire
- 2 months ago - Ligand to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference - GlobeNewsWire
- 4 months ago - Ligand Hosts 2025 Investor Day and Introduces 2026 Guidance - GlobeNewsWire